OTC: ACUT
Accustem Sciences Inc.CIK 0001850767 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade ACUT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 20, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
| Description | Three months ended September 30 2026 | Three months ended September 30 2025 | Nine months ended September 30 2026 | Nine months ended September 30 2025 |
|---|---|---|---|---|
| OPERATING EXPENSES | ||||
| Research and development expenses | 14,359 | 72,720 | 79,196 | 161,270 |
| Acquired in-process research and development expense | 1,500,000 | - | 1,500,000 | - |
| General and administrative expenses | 355,536 | 327,177 | 1,029,155 | 1,080,438 |
| Total operating expenses | 1,869,895 | 399,897 | 2,608,351 | 1,241,708 |
| LOSS FROM OPERATIONS | (1,869,895) | (399,897) | (2,608,351) | (1,241,708) |
| Income tax benefit (expense) | ||||
| NET LOSS | (1,869,895) | (399,897) | (2,608,351) | (1,241,708) |
| Net loss per share attributable to common stockholders, basic and diluted | (0.12) | (0.02) | (0.16) | (0.08) |
| Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted | 16,072,267 | 16,072,267 | 16,072,267 | 14,950,840 |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | September 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash | 15,303 | 13,929 |
| Prepaid expenses | 67,898 | 35,517 |
| Total Current Assets | 83,201 | 49,446 |
| Equipment, net | — | — |
| Other non-current assets | — | 1,500,000 |
| TOTAL ASSETS | 83,201 | 1,549,446 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable | 640,022 | 703,812 |
| Related party payable | 5,363,673 | 4,222,838 |
| Accrued expenses | 17,527 | 1,875 |
| Note Payable | 42,108 | 22,546 |
| Total Current Liabilities | 6,063,330 | 4,951,071 |
| TOTAL LIABILITIES | 6,063,330 | 4,951,071 |
| Shareholders’ Equity | ||
| Preferred stock $.001 par value; 10,000,000 shares authorized; none issued and outstanding | - | - |
| Common stock $.001 par value; 150,000,000 shares authorized; 16,072,267 shares issued and outstanding as of September 30, 2026 and 16,072,267 shares issued and outstanding as of December 31, 2025 | 16,072 | 16,072 |
| Additional paid-in capital | 6,395,293 | 6,365,446 |
| Accumulated deficit | (12,391,494) | (9,783,143) |
| TOTAL SHAREHOLDERS’ EQUITY | (5,980,129) | (3,401,625) |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 83,201 | 1,549,446 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Nine months ended September 30 2026 | Nine months ended September 30 2025 |
|---|---|---|
| Operating Activities | ||
| Net loss | (2,608,351) | (1,241,708) |
| Adjustments to reconcile net loss to net cash used in (provided by) operating activities | ||
| Depreciation | - | 418 |
| Share-based compensation | 29,847 | 65,022 |
| Expenses settled in stock | - | 79,000 |
| Acquired in-process research and development expense | 1,500,000 | - |
| Change in operating assets and liabilities: | ||
| Prepaid expenses | 56,623 | 80,981 |
| Accounts payable | (63,790) | 118,576 |
| Related party payable | 205,835 | 39,244 |
| Accrued expenses | 15,652 | (14,279) |
| Net cash used in (provided by) operating activities | (864,184) | (872,746) |
| Financing Activities | ||
| Advances from related party | 935,000 | 957,000 |
| Payments on note payable | (69,442) | (74,909) |
| Net cash used in (provided by) financing activities | 865,558 | 882,091 |
| (Decrease)/Increase in cash | 1,374 | 9,345 |
| Cash, beginning of period | 13,929 | 5,046 |
| Cash, end of period | 15,303 | 14,391 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Issuance of Note Payable for payment of prepaid expense | 87,409 | 92,597 |
| Cash paid for interest | 1,594 | 1,854 |
| Shares issued pending non-cash transaction | - | 1,500,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗